Avastin may be used for:
"Recurrent epithelial ovarian , fallopian tube or primary peritoneal cancer that is
- platinum-resistant in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan
- platinum-sensitive in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed byAvastin as a single agent (1.6) "
This approval is based on two phase III studies. One study, GOG-213, showed a 5 month longer overall survival for women with platinum sensitive OC when treated with bevacizumab and chemotherapy versus chemotherapy alone. The other study, OCEANS, showed a median progression free survival of 4 months for those receiving Avastin and chemotherapy versus those receiving placebo and chemotherapy.
Avastin had previously been approved in 2014 for women with platinum resistant ovarian cancer, fallopian tube and primary peritoneal in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan chemotherapy.
Every Day is a Blessing! Happy to see more options for women with platinum sensitive OC.